Site icon Epomedicine

Complications of Long Term Dialysis

A) Cardiovascular complications

1. Exacerbation or Precipitation of CHF – Voluminous AV Fistula

AV shunting → Decreased TPR → BP fall → Sympathetic stimulation & RAAS activation → Ventricular remodeling → Heart failure

Several studies have investigated the cut-off fistula access flow that is associated with a higher risk of high-output cardiac failure, with results ranging between 1.5 and 2.0 l/min

Requires surgical management of AV defect

2. Vascular and Cardiac calcifications –

3. Exacerbation of hypertension – Erythropoiesis Stimulating Agents (ESA)

ESA mediated increased TPR is mediated by increase in endothelins, angiotensin, impaired vascular entothelial relaxation, altered calcium levels in vascular smooth muscle cells and the release of serotonin by the platelets.

4. Hyperhomocysteinemia: defined as a plasma total homocysteine level of 12 µmol/l

5. Inadequate Intradialysis Ultrafiltration (UF)

6. Rapid electrolyte changes during dialysis session

7. Hyperlipidemia and accelerated atherosclerosis

8. Dialysis pericarditis, endocarditis

B) Gastrointestinal Complications

1. Anorexia and Nausea – Reduced dialysis dose

Anorexia has been attributed to the increase in leptins.

2. Gastritis and GI bleeding risk –

3. Hypercalcemia

4. Colonic diverticulosis – esp. in PKD

5. Ascites – Chronic volume overload

6. Angiodysplasia: submucosal capillary dilation and fibromuscular hyperplasia; important cause of EPO resistant anemia; treatment is APC (Argon Plasma Coagulation)

7. Hemosiderosis – Excessive transfusion

Note: Hemosiderosis (reversible) vs Hemochromatosis (irreversible)

8. Constipation

9. Laxative effects – Other phosphate binders

10. Pseudomembranous colitis – prolonged antibiotics

C) Anemia

1. Chronic hemolysis:

2. Iron deficiency:

3. Folate deficiency:

4. Endogenous EPO synthesis inhibition – Repeated transfusions

5. Aluminium toxicity:

6. Myelofibrosis- Severe 2⁰ hyperparathyroidism

D) Erythropoiesis stimulating agents (ESA) associated complications

1. Hypertension – onset or worsening

2. Vascular access thrombosis

3. Erythrocytosis

4. Aplastic anemia

Platelets
Increased production of microparticles
Enhanced platelet activation
Vascular endothelium
Mitogenic, chemotacticy and angiogenic effect
Increased endothelin production
Increased PAI-1 production
Vascular smooth muscle
Raises cytosolic Ca2+ concentration
Increases responses to norepinephrine, angiotensin II, and endothelin-1
Mitogenic effect
Cardiomyocytes
Enhances proliferation (neonatal)
Stimulates Na+,K+ activity

E) Bleeding Diathesis

1. Blood – Dialysor contact:

2. Heparin during HD:

3. Antiplatelets – Vascular patients

4. GI bleeding in HIV associated nephropathy: Kaposi’s sarcoma, NHL, CMV colitis

5. With PAN – Spontaneous retroperitoneal bleeding

6. Oral anticoagulants or Severe HTN – Intracerebral hemorrhage

F) Pulmonary Complications

1. Pulmonary infections

2. Pleural effusion

G) Bone Disorders

1. Adynamic bone disease – Excessive vitamin D3

2. Aluminum bone toxicity – Low bone turnover:

3. Non-aluminum osteomalacia:

4. Dialysis amyloidosis:

Hemofiltration or high-flux hemodialysis to remove 2-microglobulin can be considered.

H) Neurologic complications

1. Dialysis dementia

2. Subdural hematoma

3. Wernicke acute encephalopathy (thiamine deficiency)

4. Encephalopathy 2⁰ to biotin deficiency

5. Mononeuropathy – Median nerve compression

6. Iatrogenic complications:

7. Inter- or Intra-dialytic electrolyte imbalance:

I) Carbohydrate metabolism

1. Hypoglycemia risk maintained:

2. Decrease in insulin need:

3. Increase in insulin need:

J) Protein metabolism

1. HD – catabolic process

2. Decreased plasma creatinine in chronic HD:

5 to 8 g of free amino acids per dialysis session with low-flux dialyzers 30% greater amino acid losses with high-flux dialyzers

Uremia is a hypercatabolic state; factors involved are: low protein intake, increased plasma hypercatabolic hormones that are insufficiently degraded by the kidney (glucagon, cortisone, catecholamine), tissue resistance to anabolic hormone actions as a result of accumulation of uremic toxins. Hemodialysis largely corrects these problems by removal of the toxins, normalizing the half-life of catabolic hormones and also by allowing a normal or hyperproteic diet

K) Lipid Metabolism

1. Type IV Hyperlipoproteinemia in CKD

2. HD – doesn’t correct; may aggravate

3. More pronounced in – DKD and Nephrotic syndrome

L) Cutaneous manifestations

1. Pruritus

2. Xerosis

3. Pigmentations

4. Cutaneous calcifications – 2⁰ hyperparathyroidism

5. HD-associated bullous dermatitis:

M) Gonadal functions

1. Improved sexual function in male – without increase in testosterone

2. Reappearance of menstruation in females – but anovulatory cycles

3. Subfertility – rarely become pregnant

4. Rarely, carry pregnancy to term:

N) Vitamins

1. Causes of deficiency – Water soluble vitamins:

2. Supplementation:

O) Immunological functions

1. T-lymphocyte activation → ↑APCs and IL-2 → Worsening of inflammatory state

2. Depressed normal antibody reactions

3. ↑ Increased autoantibody and anti-ethylenoxid antibodies

4. Neutrophilic and Complement activation – Protease and ROS release:

P) Viral Infections

1. Hepatitis B and C

2. HIV

Q) Acquired Polycystic Kidney Disease

1. Associated with:

2. Increased risk of – urothelial neoplasia

R) Complications induced by Primary Renal Disease

1. Rapid decline of residual renal function:

2. Bone disease:

3. Reccurence and comorbidities:

References:
  1.  Chronic complications in hemodialysis: correlations with 
    primary renal disease I. A. CHECHERIŢĂ, FLAVIA 
    TURCU, R. F. DRAGOMIRESCU, A. CIOCÂLTEU
  2.  Hemodialysis Complications - Jonathan Himmelfarb, MD
Exit mobile version